Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.
You may also be interested in...
Alnylam CEO John Maraganore: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
In part two of this interview, the Alnylam chief executive discusses the thought process behind the biotech’s cutback in staff this past January and its $87 million cash raise in February.
Alnylam CEO John Maraganore – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.
Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model,
From offices in North Carolina and Hangzhou, the start-up will in-license compounds to sell in China while developing its own candidates.